Spots Global Cancer Trial Database for advanced cholangiocarcinoma
Every month we try and update this database with for advanced cholangiocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | NCT04088188 | Advanced Cholan... Metastatic Chol... Unresectable Ch... | Cisplatin Gemcitabine Ivosidenib Pemigatinib | 18 Years - | Academic and Community Cancer Research United | |
| NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma | NCT06420349 | Advanced Cholan... Metastatic Chol... Refractory Chol... Stage III Hilar... Stage III Intra... Stage IV Hilar ... Stage IV Intrah... | Biospecimen Col... Computed Tomogr... Heat Shock Fact... Magnetic Resona... Positron Emissi... Ultrasound-Guid... | 18 Years - | Mayo Clinic | |
| Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | NCT04507503 | Advanced Cholan... | TAS-120 | 18 Years - | Taiho Oncology, Inc. | |
| A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | NCT02150967 | Advanced Cholan... FGFR2 Gene Muta... | BGJ398 (infigra... | 18 Years - | QED Therapeutics, Inc. | |
| Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma | NCT05823311 | Advanced Cholan... | Lenvatinib, tis... Gemcitabine and... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | NCT02150967 | Advanced Cholan... FGFR2 Gene Muta... | BGJ398 (infigra... | 18 Years - | QED Therapeutics, Inc. | |
| AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease | NCT05791448 | Advanced Cholan... Advanced Hepato... Advanced Malign... Metastatic Mali... Refractory Mali... Stage III Hepat... Stage IV Hepato... | Biospecimen Col... Computed Tomogr... Magnetic Resona... RNA Transcripti... | 18 Years - | University of Southern California | |
| Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma | NCT05823311 | Advanced Cholan... | Lenvatinib, tis... Gemcitabine and... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma | NCT03982680 | Advanced Cholan... | Toripalimab Gemcitabine 5- fluorine pyr... | 18 Years - 70 Years | Jiangmen Central Hospital | |
| A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | NCT02150967 | Advanced Cholan... FGFR2 Gene Muta... | BGJ398 (infigra... | 18 Years - | QED Therapeutics, Inc. | |
| Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion | NCT06439485 | Advanced Cholan... FGFR2 Fusion | Pemigatinib Atezolizumab Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | NCT05805956 | Advanced Solid ... Advanced Lung C... Advanced Gastri... Advanced Cholan... | IMM2902 | 18 Years - 75 Years | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | |
| Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol | NCT00973713 | Cholangiocarcin... | RAD001 | 18 Years - | Austin Health | |
| NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma | NCT06420349 | Advanced Cholan... Metastatic Chol... Refractory Chol... Stage III Hilar... Stage III Intra... Stage IV Hilar ... Stage IV Intrah... | Biospecimen Col... Computed Tomogr... Heat Shock Fact... Magnetic Resona... Positron Emissi... Ultrasound-Guid... | 18 Years - | Mayo Clinic | |
| Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) | NCT02989857 | Advanced Cholan... Metastatic Chol... | AG-120 Placebo | 18 Years - | Servier | |
| Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma | NCT05532059 | Advanced Cholan... | Lenvatinib, tis... gemcitabine and... | 18 Years - 85 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron | NCT02982720 | Advanced Cholan... | Pembrolizumab Sylatron | 18 Years - | Hoosier Cancer Research Network | |
| Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | NCT04507503 | Advanced Cholan... | TAS-120 | 18 Years - | Taiho Oncology, Inc. | |
| Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma | NCT03982680 | Advanced Cholan... | Toripalimab Gemcitabine 5- fluorine pyr... | 18 Years - 70 Years | Jiangmen Central Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
